Bispecific monoclonal antibody targeting tumor-associated antigen (BsAb (when referring to bispecific monoclonal antibody); no unique abbreviation for the specific target described)

A **bispecific monoclonal antibody targeting tumor-associated antigen** is an engineered protein designed to bind simultaneously to two different targets—one arm binds specifically to an antigen present on cancer cells (**tumor-associated antigen**, TAA), while the other arm typically binds either another epitope or more commonly an activating molecule found on immune effector cells such as T-cells (**CD3**) or NK-cells (**CD16**) [1][2][4]. This dual binding brings immune effector cells into close proximity with cancerous tissue, facilitating direct killing of malignant cells through mechanisms like cytotoxic granule release. These agents represent a major advance over traditional monoclonal antibodies because they can overcome resistance mechanisms by engaging multiple pathways at once. However, "Tumor-associated antigen-bound bispecific monoclonal antibody" is not itself one unique molecular entity but rather describes any member within this large class; each actual drug has its own precise specificity based on which TAA(s) it recognizes [2][3]. If you need structured data about *a specific* bsAb drug or *a defined* tumor-antigen/receptor pair—for example "Blinatumomab"—please specify so that information can be tailored accordingly.

Other names

Bispecific antibody targeting tumor-associated antigenTumor-targeted bispecific antibodyTAA-targeting bispecific mAbBsAb against TAA

Redirects immune effector cells to tumor cells by binding both the **tumor-associated antigen** and an activating molecule on immune cells such as CD3 or CD16[1][4]. Induces targeted cytotoxicity via immune synapse formation between T/NK cells and cancer cell. May block two signaling pathways simultaneously if designed for dual pathway inhibition.[6]